ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Scientist I/II, Modality Engineering at Lexeo Therapeutics - ApplyBlast

Scientist I/II, Modality Engineering

Lexeo Therapeutics

7 days ago

New York, New York, United States

Onsite

Full Time

Junior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Scientist I/II, Modality Engineering role involves selecting and managing CROs for oligonucleotide synthesis, designing and overseeing oligonucleotide conjugates, and engineering AAV capsids and vectors. The position requires hands-on experience with ASO/siRNA chemistry, analytical characterization, and NGS data analysis to improve potency and production yield. This role collaborates with cross-functional teams to define screening cascades, assess developability, and support molecule advancement through process development.

Responsibilities

Select and manage CROs for oligonucleotide synthesis and bioconjugation
Design and oversee oligonucleotide conjugates using peptides or antibodies
Engineer AAV capsids and conduct cloning and vector production

Skills

Qualifications

PhD in chemistry, chemical biology, biochemistry, molecular biology, or a related fieldMS with 5+ years of industry experience

About Lexeo Therapeutics

lexeotx.com

Headquarters

New York, New York, United States

Company Size

11-50 employees

Founded

2018

View Profile

Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company advances high-impact genetic medicine candidates targeting genetically mediated cardiovascular diseases—including Friedreich ataxia, arrhythmogenic cardiomyopathy, desmoplakin cardiomyopathy, and hypertrophic cardiomyopathy—as well as APOE4-associated Alzheimer's disease. Building on research from Weill Cornell Medicine and UC San Diego, Lexeo prioritizes efficient development, advanced manufacturing, and strategic partnerships to deliver curative genetic therapies.